2024-03-28T23:01:06Z
https://u-ryukyu.repo.nii.ac.jp/oai
oai:u-ryukyu.repo.nii.ac.jp:02015938
2022-10-31T07:47:17Z
1642838163960:1642838198944:1642838199408:1642838207689
1642838403551:1642838412624
[総説]北米における感性脳腫癖に対する遺伝子泊癖の状況 : 文部省在外研究報告
Report of the ministry of education reserearch program on the present state of gene therapy for malignant brain tumor in North America
宮城, 航一
Miyagi, Koichi
brain tumor
gene therapy
glioblastoma
viral vector
One of the most difficult problem in malignant glioma therapy is the elimination of invasive glioma cell in normal brain tissue. The solution to this problem is the application of gene therapy. For further research and developement of this gene therapy, I had an oppotunity to visit the NIH and other Institutes in North America. NIH had a clinical protocol of gene therapy for malignant glioma. This clinical protocol was started in December 1992. The result has not yet been reported. Recombinant retrovirus producer cell was injected stereotactically in to the brain tumor. Seven days later ganciclovir treatment was given for 14 days. For two cases, the brain tumor was reoperated few days after the producer cell injection, that is before ganciclovir therapy. Percentage of target gene transduced cells was less than 0.2%. However for 5 out of 16 lesions, tumor size became less than 50% of pre-treatment size. They concluded that bystander effect contributed to the decrease in the tumor size. There was neither toxicity nor replication of competent retrovirus from peripheral blood lymphocyte. Genetic Therapy Incorporation (GTI) and Sandoz Pharma Ltd have extended their phase II protocol to 10 Institutes each in the U.S.A, Europe and Canada. Suicide gene therapy (HSVtk/GCV system) and immuno-modified gene therapy are usually applied to malignant tumor. The genes ofcytokine, adhesion molucles or major histocompatibility complex are introduced into the tumor-infiltrated lymphocyte, lymphokineactivated lymphocyte or tumor cell. Target gene transduced lymphocytes secrete cytokines and attract the cytotoxic T lymphocyte into the tumor tissue. On the other hand, transduced tumor cells are used as the tumor vaccine. Usually, suicide gene therapy is applied to brain tumor, whereas the tumor vaccines are applied to melanoma and renal cell carcinoma, because these tumors have a high antigenicity. Unfortunately, NIH clinical results reveal that the transduction ratio of recombinant retroviral vector into the glioma cells is low. Therefore, the most important area in the gene therapy for malighant glioma is to develop a method to transfer the target gene into the infiltrated glioma cell. For clinical application, it is advisable to obtain the vector producer cells from GTI since the confirmation of safety and quality of the vector is extremely expensive. However, it is better for us to develop our own basic research program.
論文
http://purl.org/coar/resource_type/c_6501
琉球医学会
Ryukyu Medical Association
1996
VoR
1346888X
0289-1530
AN10369445
琉球医学会誌 = Ryukyu Medical Journal
1
16
15
11
jpn
open access
琉球医学会